Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544301 | 0.72 | SIRT6 (0.44) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL11853980 | 0.70 | ALOX5 (0.56) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL6815260 | 0.69 | GAA (0.69) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL899512 | 0.69 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL29793662 | 0.69 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL6811691 | 0.68 | GAA (0.71) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL6141689 | 0.67 | POLB (0.60) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL28021548 | 0.67 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL10913298 | 0.66 | HSD17B10 (0.56) | ALDH1A1LMNAMAPTSMN1; SMN2GAA | |
| SCHEMBL2103553 | 0.66 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217022-B2 | Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for tumour treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2012-07-10 | — | — | US | disclosed |
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BAD | ALDH1A1 2073/4885LMNA 1335/4885MAPT 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.